

DIVERSIFICATION AND MODULATION OF THE AGGREGATION PATHWAYS OF PROTEINS IN THE PRESENCE OF EXTERNAL ADDITIVES

SHIVNETRA SAHA



DEPARTMENT OF CHEMISTRY
INDIAN INSTITUTE OF TECHNOLOGY DELHI
MARCH 2017

©Indian Institute of Technology Delhi (IITD), New Delhi, 2017

DIVERSIFICATION AND MODULATION OF THE AGGREGATION PATHWAYS OF PROTEINS IN THE PRESENCE OF EXTERNAL ADDITIVES

by

SHIVNETRA SAHA
Department of Chemistry

Submitted

in fulfillment of the requirements of the degree of Doctor of Philosophy
to the



INDIAN INSTITUTE OF TECHNOLOGY DELHI

MARCH 2017

CERTIFICATE

This is to certify that the thesis entitled, “*Diversification and modulation of the aggregation pathways of proteins in the presence of external additives*”, being submitted by **Ms. Shivnetra Saha** to the **Indian Institute of Technology Delhi** for the award of the degree of **Doctor of Philosophy** in Chemistry is a record of bona fide research work carried out by her. Ms. Shivnetra Saha has worked under my guidance and supervision and has fulfilled the requirements for the submission of this thesis, which to my knowledge has reached the requisite standard.

The results contained in this dissertation have not been submitted in part or full to any other University or Institute for the award of any degree or diploma.

(Dr. Shashank Deep)

Associate Professor,

Department of Chemistry

Indian Institute of Technology Delhi

New Delhi-110016

ACKNOWLEDGEMENTS

I owe this thesis to HIM

I do not know where to begin from. Any sequence of acknowledgment will be an injustice to the one following another. But I have to start, and I do so with Dr. Shashank Deep. It dates back to the times when he taught me Chemical Kinetics in my Masters. In 2010. From then, up till now, I cannot thank him any less for being what he has been. The journey of research saw numerous crests and troughs. But with him being there, the troughs were so much easy to deal with. I cannot thank him enough for being more than patient and for being so tolerant. Being under his supervision has taught me so much that I wonder if books could ever provide me those. Today, I believe, I have a gem with me- a gem which I got as a gift for being under his supervision- I have learnt to think independently, and work independently. Of course, in the midst of all, he was there to support whenever I needed. I could not have asked for anyone or anything better.

I also thank all the past and the present Head of the Departments, all the faculty members and staff for providing the necessary infrastructure for carrying out the research work. I would also like to specially thank my SRC members Dr. Apurba Sau (external expert, National Institute of Immunology, Delhi), Dr. Pramit Kumar Choudhury and Prof. Siddharth Pandey.

I am extremely grateful to my past seniors for every little thing they have contributed to the completion of my PhD. Anurag Sir for teaching me the first aggregation experiments and the curve fitting, Unnati Ma'am for providing the warmth of love and affection, Komal Ma'am for teaching me to see beyond the curve-fittings, and Nayeem Sir for bestowing me with the perfect guidance and wisdom.

The entire journey would have been impossible without the cooperation of my lab mates Vinay, Preeti, Nidhi (Kaur) and Nidhi (Katyal) who have contributed in one way or the other to keep the research-train moving. An equally important part has been played by my friends, Jayanta, Sandip and Sanjib, whom I always found around me (including the tea sessions!), to lighten up any moment- something which was so essential to live through the ordeals of research. I would also like to particularly thank M.Sc students Deepak and Rupali. I also thank Raktim, Aayushi and Priya.

I would like to thank Ashhar Sir for teaching me the ABCs of protein expression and purification. I cannot thank him enough for being so patient with me- my repeated questions about bacteria never came to an end, and neither did his patience. The journey towards the end would not have been so easy had Amrita Ma'am not come. I am so grateful for all the lively moments we have shared together in the lab, and beyond. Our tea times were my lifelines!

My bundle of acknowledgements will always have a special place for my friends, Rusha and Sonali. Life had been so great since the time I met them in IIT. They have been the witness to every moment of mine- be it anger, sorrow, happiness or madness. Starting from class notes to little scientific discussions- they were in, and had been, everything.

My PhD would not have ended in the same wonderful way had it not been for the relentless support of my husband, Atulan, and my in-laws. Atulan has always been at the receiving end of everything since the time I came to know him, and has been so with immense patience and care. The cooperation from my in-laws has been an essential component of this journey, and I cannot thank them enough for everything.

Whatever, whoever, wherever I am today, is all because of my father and mother. And my elder sister. She was the one to foresee that I will fit into research, from the times I did not even understand what research meant, and what it was all about. My camaraderie with research today vouches that her realization was so right. I do not even know from where to start thanking my parents. They have always encouraged and nurtured my curiosity and creativity (and destructivity too, in some cases!) and have taught me to think and act independently within limits. I would not have been sane today had it not being for their constant and unending inspiration and support in each and every ups and downs. The unparalleled solace which I got from them is perhaps what drove me here today in writing this thesis.

I would like to thank all my teachers, beginning from nursery to college to IIT, who helped to bring out the best possible in me. Last, but not the least, I ask for forgiveness from anybody I have missed out above.

Shivnetra Saha

ABSTRACT

The thesis titled “**Diversification and modulation of the aggregation pathways of proteins in the presence of external additives**” presents a study of the diverse behaviour of proteins under different environmental conditions. The key to controlling or manipulating the aggregation of proteins lies in the mechanistic understanding of this process, and one such route is to understand the kinetics and the thermodynamics of aggregation. The phenomenon has captured considerable attention, majorly because of its involvement in many neurodegenerative diseases, and also because of its undesirable, spontaneous occurrence during the processing and manufacturing of protein-based therapeutics. A brief description of the chapters is presented below.

Chapter 1 (Introduction) presents a brief idea about the necessity of studying the process of protein aggregation, the progresses till now in this field, various broad classes of mechanisms of aggregation and how the models developed/improved over the course of time. It also discusses about the intermediates in the aggregation pathway, and the various structural tools which are available for detecting the presence of various species in the aggregation pathway. **Chapter 2 (Materials and methodologies)** describes the proteins used in this study, their expression and purification protocol (as required), the procurement of the proteins and other chemicals used throughout the study, and the instruments used in the study. **Chapter 3 (Switch in the aggregation pathway of bovine serum albumin mediated by electrostatic interactions)** demonstrates that a strong denaturant, guanidinium hydrochloride (GdnHCl), can delay and alter the inherent aggregation pathway of bovine serum albumin (BSA) from downhill polymerization to a nucleated polymerization. It is hypothesized that such an alteration is closely connected to the conformational population of the protein, and ion-binding to such an ensemble. The study shows that the behavior in GdnHCl is not unique to it, but occurs in a certain class of cosolutes- those

which are charged and bind to BSA. **Chapter 4 (A paradox in the stability and aggregation of bovine serum albumin: uniqueness of a cosolute)** works as sequel to Chapter 3, wherein the aggregation has been carried out in the presence of urea, ethanol, and arginine. The three additives do not show a uniform behaviour towards unfolding and aggregation. Although partial unfolding is a prerequisite for the initiation of aggregation, this study shows that the phenomenon can be dominated by the presence of a particular cosolute too. **Chapter 5 (Modulations in the self-assembly of bovine serum albumin by enhanced depolymerisation and condensation induced upon stirring)** shows that stirring the solution of the BSA-CTAB system resulted into a reduced extent of aggregation, as compared to the unstirred solution. The apparent saturation phase phase which is attained faster when the solution is stirred, is a consequence of the condensation of aggregates predominating the aggregation pathway, beyond a certain aggregate concentration. The rapid approach to the condensation process ultimately leads to lesser incorporation of the monomers into the aggregates, thus reducing the aggregation. **Chapter 6 (Differential influence of additives on the various stages of insulin aggregation)** describes the effect of sugars and polyols on the aggregation of insulin which occurs by a typical nucleation-growth mechanism. Sugars and polyols affect the lag time and the rate constant of growth to different extents, suggesting that these additives affect both the pre- and post-nucleation processes. Sucrose and ethylene glycol effectively reduce the aggregation, whereas mannitol is not effective in suppressing the overall aggregation. However, it can delay the aggregation process. The varying behaviour of different additives suggests their interference in the different stages of aggregation, affecting the aggregation intermediates differently. In **Chapter 7 (Glycerol inhibits the primary pathways and transforms the secondary pathway of insulin aggregation)**, it is shown that glycerol could transform the secondary pathway of aggregation of insulin from fragmentation to

heterogeneous nucleation in a concentration dependent manner. Such a change in the secondary pathway was also accompanied by the formation of longer fibrils. The analysis of the kinetic traces suggested that the inhibitory effect was most significant on the primary pathways, although secondary nucleation and elongation were also inhibited. **Chapter 8 (Inverse effects of additives on the fibrillation and oligomerization of α -synuclein)** presents the aggregation of α -synuclein in copper sulphate and glycerol, in the presence and absence of dopamine. Both the additives increase the aggregation of this protein. However, it has been shown here that toxic oligomers which are usually promoted by dopamine, do not form in the presence of copper. Glycerol, however, promotes the formation of these toxic oligomers. We speculate that it is the binding of copper to the fibrils which stabilizes them to such an extent that the oligomers do not persist for long, and go all the way to form fibrils. Glycerol perhaps does not interact with the fibrils but facilitates the dopamine-oligomer interaction, leading to the stabilization of the oligomers. **Chapter 9 (Summary and future prospects)** presents the highlights of the study. It summarizes the diverse/similar behaviour a protein can exhibit under similar/different conditions, respectively. The pathway a protein takes, or the aggregates they form, can be manipulated by modifying the external conditions.

सार

"बाहरी योजक की उपस्थिति में प्रोटीन के एकत्रीकरण मार्गों के विविधीकरण और मॉडलन" नामक थीसिस विभिन्न पर्यावरणीय परिस्थितियों में प्रोटीनों के विविध व्यवहार का एक अध्ययन प्रस्तुत करता है। प्रोटीन के एकत्रीकरण को नियंत्रित करने या जोड़ तोड़ने की कुंजी इस प्रक्रिया की यंत्रवत् समझ में निहित है, और एक ऐसा मार्ग है कि कैनेटीक्स और एकत्रीकरण के ऊष्मप्रवैगिकी को समझना है। इस घटना ने काफी ध्यान आकर्षित किया है, जो कि कई neurodegenerative बीमारियों में इसकी भागीदारी के कारण, और प्रोटीन आधारित चिकित्सा विज्ञान के प्रसंस्करण और निर्माण के दौरान इसकी अवांछनीय, सहज घटना के कारण भी। अध्यायों का एक संक्षिप्त विवरण नीचे प्रस्तुत किया गया है। अध्याय 1 (परिचय) प्रोटीन एकत्रीकरण की प्रक्रिया का अध्ययन करने की आवश्यकता के बारे में एक संक्षिप्त विचार प्रस्तुत करता है, इस क्षेत्र में अब तक की प्रगति, एकत्रीकरण के विभिन्न व्यापक कक्षाएं और कैसे समय के दौरान मॉडल विकसित / सुधारा। यह एकत्रीकरण मार्ग में मध्यवर्ती के बारे में भी चर्चा करता है, और विभिन्न संरचनात्मक उपकरण जो एकत्रीकरण मार्ग अध्याय 2 (सामग्री और पद्धतियों) में विभिन्न प्रजातियों की उपस्थिति का पता लगाने के लिए उपलब्ध हैं, इस अध्ययन में प्रयुक्त प्रोटीन का वर्णन करता है, उनकी अभिव्यक्ति और शुद्धि प्रोटोकॉल (आवश्यकतानुसार), पूरे अध्ययन में प्रयुक्त प्रोटीन और अन्य रसायनों की खरीद, और अध्ययन में इस्तेमाल किए गए उपकरण। अध्याय 3 (इलेक्ट्रोस्टैटिक इंटरैक्शन द्वारा मध्यस्थता वाले गोजाइन सीरम एल्बिन के एकत्रीकरण मार्ग में स्विच करें) दर्शाता है कि एक मजबूत डिस्ट्रेंट, ग्नाइडीनियम हाइड्रोक्लोराइड (जीडीएनएचसीएल), उतार-चढ़ाव पॉलिमराइजेशन से गोजातीय सीरम एल्बूमिन (बीएसए) के अंतर्निहित एकत्रीकरण मार्ग को एक न्यूक्लियोपॉलीमराइजेशन ऐसा प्रतीत होता है कि इस तरह के परिवर्तन प्रोटीन की गठनात्मक आबादी से निकटता से जुड़ा हुआ है, और इस तरह के कलाकारों के लिए आयन-बाध्यकारी है। अध्ययन से पता चलता है कि जीडीएनएचसीएल में व्यवहार इसके लिए अनूठा नहीं है, लेकिन एक निश्चित श्रेणी के कॉस्मोलिट्स में होता है- जो कि चार्ज और बीएसए से जुड़े होते हैं अध्याय 4 (गोजातीय सीरम एल्बूमिन की स्थिरता और एकत्रीकरण में एक विरोधाभास: एक सुसंस्कृतता की विशिष्टता) अध्याय 3 की अगली कड़ी के रूप में काम करता है, जिसमें एकत्रीकरण यूरिया, इथेनॉल और आर्गिनिन की उपस्थिति में किया गया है। तीन योजक उभरने और एकत्रीकरण के प्रति एक समान व्यवहार नहीं दिखाते हैं। यद्यपि आंशिक खुलासा एकत्रीकरण की शुरुआत के लिए एक शर्त है, इस अध्ययन से पता चलता है कि इस घटना पर एक विशेष संकाय की मौजूदगी भी हो सकती है। अध्याय 5 (उत्तेजित depolymerization और संयम पर प्रेरित condensation द्वारा बोवाइन सीरम Albumin के आत्म-विधानसभा में मॉड्यूल) पता चलता है कि बीएसए-सीटीएबी प्रणाली के समाधान को हल करने के कारण एकीकरण के एक सीमित हद तक परिणामस्वरूप, अनसुलझे समाधान की तुलना में स्पष्ट संतृप्ति चरण चरण, जो समाधान प्राप्त हो जाता है, जब तेजी से प्राप्त होता है,

तो एक निश्चित सकल एकाग्रता से परे, एकत्रीकरण मार्ग को प्राथमिकता देने वाले समुच्चय का एक परिणाम है। संक्षेपण प्रक्रिया के लिए तेजी से दृष्टिकोण अंततः मोनोमर्स के समुच्चय को कम निगलना होता है, जिससे एकत्रीकरण कम हो जाता है। अध्याय 6 (इंसुलिन एकत्रीकरण के विभिन्न चरणों में additives के विभेदक प्रभाव) इंसुलिन के एकत्रीकरण पर शर्करा और पॉलीओल्स के प्रभाव का वर्णन करता है जो एक विशिष्ट न्यूक्लेयेशन-ग्रोथ मैकेनाइजेशन द्वारा होता है। शुगर्स और पॉलीओल्स समय के अंतराल को प्रभावित करते हैं और अलग-अलग विस्तार में वृद्धि की दर को प्रभावित करते हैं, यह सुझाव देते हैं कि ये योजक पूर्व और पोस्ट-न्यूक्लेयेशन प्रक्रियाओं को प्रभावित करते हैं। सुक्रोज और इथाइलीन ग्लाइकॉल एकत्रीकरण को प्रभावी ढंग से कम करते हैं, जबकि कुल एकाग्रता को दबाने में मनिटोल प्रभावी नहीं है। हालांकि, यह एकत्रीकरण प्रक्रिया को देरी कर सकता है। विभिन्न योजक के अलग-अलग व्यवहार एकत्रीकरण के विभिन्न चरणों में उनके हस्तक्षेप का सुझाव देते हैं, जो एकत्रीकरण मध्यवर्ती को अलग-अलग तरीके से प्रभावित करते हैं। अध्याय 7 में (ग्लिसरॉल प्राथमिक पथ को रोकता है और इंसुलिन एकत्रीकरण के माध्यमिक मार्ग को परिवर्तित कर देता है), यह दिखाया जाता है कि ग्लिसरॉल एकाग्रता निर्भर तरीके से विषुव न्यूक्लेयेशन को विखंडन से इंसुलिन के एकत्रीकरण के माध्यमिक मार्ग को बदल सकता है। माध्यमिक मार्ग में इस तरह के बदलाव में लंबे समय तक तंतुओं का गठन किया गया था। गतिज निशान के विश्लेषण ने सुझाव दिया कि निषेधात्मक प्रभाव प्राथमिक रास्ते पर सबसे महत्वपूर्ण था, हालांकि माध्यमिक न्यूक्लेयेशन और बढ़ाव भी हिचकते थे। अध्याय 8 (α -synuclein के फाइब्रिलेशन और ऑल्लिगोमराइजेशन पर additives के प्रतिकूल प्रभाव) कॉपर सल्फेट और ग्लिसरॉल में α -synuclein के एकत्रीकरण को प्रस्तुत करता है, जिसमें डोपामाइन की मौजूदगी और अनुपस्थिति में दोनों additives इस प्रोटीन के एकत्रीकरण में वृद्धि। हालांकि, यहां यह दिखाया गया है कि आमतौर पर डोपामाइन द्वारा विषैले ऑल्लिगोमरों को बढ़ावा दिया जाता है, तांबे की उपस्थिति में नहीं होता है। ग्लिसरॉल, हालांकि, इन विषैले oligomers के गठन को बढ़ावा देता है। हम अनुमान लगाते हैं कि तांबा की बाध्यता उन तंतुओं को बंधी होती है जो उन्हें ऐसी हद तक स्थिर करती है कि ओल्लिगोमर्स लंबे समय तक टिके नहीं करते हैं, और तंतुओं का निर्माण करने के लिए सभी तरह से जाते हैं। ग्लिसरॉल शायद तंतुओं के साथ बातचीत नहीं करता है लेकिन डोपामाइन-ऑल्लिगोमर इंटरैक्शन की सुविधा प्रदान करता है, जिससे ओल्लिगोमर्स के स्थिरीकरण में वृद्धि होती है। अध्याय 9 (सारांश और भविष्य की संभावनाएं) अध्ययन के मुख्य आकर्षण प्रस्तुत करता है। यह विविध / समान व्यवहार को सारांशित करता है कि एक प्रोटीन क्रमशः समान / भिन्न परिस्थितियों में प्रदर्शित हो सकता है। एक प्रोटीन लेता मार्ग, या जो समुच्चय होता है, बाहरी स्थितियों को संशोधित करके इसका उपयोग किया जा सकता है।

CONTENTS

	Page No.
Certificate	I
Acknowledgements	III
Abstract (English)	VII
Abstract (Hindi)	XI
Contents	XIII
List of Figures	XXIII
List of Tables	XXXV
List of Schemes	XXXVII
List of Abbreviations	XXXIX
CHAPTER 1. INTRODUCTION	
1.1 Introduction	3
1.2 Protein aggregation kinetics: timeline and pathways	8
<i>1.2.1 Simple nucleation-elongation mechanism (homogeneous nucleation)</i>	9
<i>1.2.1.1 General equation for systems aggregating through primary nucleation</i>	11
<i>1.2.2 Homogenous nucleation followed by secondary pathways</i>	13
<i>1.2.2.1 Heterogeneous nucleation</i>	13
<i>1.2.2.2 Fragmentation</i>	14
<i>1.2.2.3 Branching</i>	16
<i>1.2.2.4 General equation for systems aggregating via secondary pathways</i>	17
<i>1.2.3 Downhill polymerization</i>	19
<i>1.2.4 The models in a nutshell</i>	21

1.3 A closer look into the nucleus	24
<i>1.3.1 Free energy profile for nucleation and elongation</i>	24
<i>1.3.2 Critical and super critical concentration</i>	26
<i>1.3.3 Thermodynamic and structural nucleus</i>	28
<i>1.3.4 Prediction of size of the nucleus</i>	30
<i>1.3.5 Effect of seeding on the aggregation pathway</i>	34
1.4 Intermediates in aggregation pathways	35
1.5 Time course of aggregation	36
<i>1.5.1 Early time and late time behaviour in presence and absence of secondary Pathways</i>	36
<i>1.5.2 Significance of the time course of aggregation</i>	39
1.6 Fitting and extracting parameters from the aggregation kinetics data	42
1.7 Amorphous protein aggregation	45
1.8 Effect of external agents on the aggregation of protein	46
1.9 Thermodynamic perspective of protein aggregation	49
1.10 Structural tools: monitoring aggregation and its intermediates	50
1.11 Origin of the problem in the context of this thesis	52
1.12 Outline of the present research problem	55
1.13 References	59

CHAPTER 2. MATERIALS AND METHODOLOGIES

2.1 Introduction	71
2.2 Materials	71

2.3 Techniques	71
2.3.1 <i>UV-visible spectroscopy</i>	71
2.3.2 <i>Fluorescence spectroscopy</i>	73
2.3.3 <i>Circular dichroism spectroscopy</i>	76
2.3.4 <i>Dynamic light scattering</i>	77
2.3.5 <i>Size exclusion chromatography</i>	78
2.3.6 <i>Native -Polyacrylamide gel electrophoresis (Native-PAGE)</i>	80
2.3.7 <i>Transmission electron microscopy</i>	80
2.3.8 <i>Fluorescence microscopy</i>	81
2.4 Data Analysis	81
2.5 References	85

CHAPTER 3. SWITCH IN THE AGGREGATION PATHWAY OF BOVINE SERUM ALBUMIN MEDIATED BY ELECTROSTATIC INTERACTIONS

3.1 Introduction	89
3.2 Materials and Methods	90
3.2.1 <i>Chemicals</i>	90
3.2.2 <i>Stock Solutions</i>	90
3.2.3 <i>Aggregation kinetics</i>	91
3.2.4 <i>Stopped-Flow Fluorescence</i>	92
3.2.5 <i>Dynamic Light Scattering</i>	92
3.2.6 <i>Zeta Potential</i>	92
3.2.7 <i>Size Exclusion Chromatography</i>	93

3.2.8 <i>Transmission Electron Microscopy</i>	93
3.2.9 <i>Data Analysis</i>	93
3.3 Results and discussion	94
3.4 Conclusion	119
3.5 References	123

CHAPTER 4. A PARADOX IN THE STABILITY AND AGGREGATION OF BOVINE SERUM ALBUMIN: UNIQUENESS OF A COSOLUTE

4.1 Introduction	129
4.2 Materials and Method	130
4.2.1 <i>Chemical</i>	130
4.2.2 <i>Solutions</i>	130
4.2.3 <i>Aggregation Assay</i>	130
4.2.4 <i>Dynamic Light Scattering</i>	131
4.3 Result and discussion	131
4.4 Conclusion	140
4.5 References	143

CHAPTER 5. MODULATION IN THE SELF-ASSEMBLY OF BOVINE SERUM ALBUMIN BY ENHANCED DEPOLYMERISATION AND CONDENSATION INDUCED UPON STIRRING

5.1 Introduction	147
5.2 Materials and methods	149
5.2.1 <i>Chemicals</i>	149

5.2.2 Stock Solutions	149
5.2.3 Aggregation kinetics.....	149
5.2.4 Fluorescence Spectroscopy.....	150
5.2.5 Size Exclusion Chromatography.....	150
5.2.6 Data Analysis.....	150
5.3 Result and discussion.....	151
5.3.1 Modulations in the aggregation induced by stirring.....	151
5.3.2 Aggregation in the presence of glycerol.....	155
5.3.3 Each flat phase represents a reversible stage in the aggregation process.....	156
5.3.4 Stirring perturbs the equilibrium and increases the depolymerisation.....	158
5.3.5 Monomers are depleted only at long times.....	160
5.3.6 Insoluble aggregates do not seed aggregation of the BSA-CTAB system.....	163
5.3.7 Stirring promotes condensation of larger aggregates.....	164
5.4 Conclusions.....	169
5.5 References.....	172

CHAPTER 6. DIFFERENTIAL INFLUENCE OF ADDITIVES ON THE VARIOUS STAGES OF INSULIN AGGREGATION

6.1 Introduction.....	177
6.2 Materials and methods.....	179
6.2.1 Chemicals.....	179
6.2.2 Kinetics of the aggregation of insulin using turbidity measurements.....	179
6.2.3 CD spectroscopy.....	180

6.2.4	<i>Fluorescence Spectroscopy</i>	181
6.2.5	<i>Effect of additives on the aggregation of insulin</i>	181
6.2.6	<i>Fluorescence microscopy of the aggregates</i>	181
6.2.7	<i>Measurment of density and viscosity of the additives</i>	182
6.2.8	<i>Effect of temperature on the aggregation kinetics of insulin</i>	182
6.3.	Results	183
6.3.1	<i>CD spectroscopy of insulin at different temperatures in presence and absence of additives</i>	183
6.3.2	<i>The aggregation of insulin at 333 K</i>	184
6.3.3	<i>The lag phase</i>	188
6.3.4	<i>The growth phase</i>	189
6.3.5	<i>Extent of aggregation</i>	190
6.3.6	<i>Morphology of the aggregates in the presence and absence of additives</i> ..	190
6.3.7	<i>Kinetics of aggregation under the condition of same solvent viscosity</i>	192
6.3.8	<i>Activation energy of aggregation of insulin in the presence of additives</i> ...	193
6.3.9	<i>Fluorescence spectroscopy of insulin in presence of additives</i>	195
6.3.10	<i>Effect of NaCl on the aggregation of insulin in the presence of different additives</i>	197
6.3.11	<i>Effect of pH on the aggregation of insulin in the presence of additives</i> ...	198
6.4	Discussion	199
6.5	Conclusions	210
6.6	References	212

**CHAPTER 7. GLYCEROL INHIBITS THE PRIMARY PATHWAYS AND MODIFIES
THE SECONDARY PATHWAY OF INSULIN AGGREGATION**

7.1 Introduction	219
7.2 Materials and methods	221
7.2.1 <i>Chemicals</i>	221
7.2.2 <i>Stock solutions</i>	221
7.2.3 <i>Aggregation kinetics</i>	222
7.2.4 <i>Seeding experiment</i>	222
7.2.5 <i>Thermal denaturation of insulin</i>	223
7.2.6 <i>Transmission Electron Microscopy</i>	223
7.2.7 <i>Fluorescence Microscopy</i>	223
7.2.8 <i>Isothermal Titration Calorimetry (ITC)</i>	223
7.2.9 <i>Kinetic analysis of the aggregation reactions</i>	224
7.3 Result and discussion	226
7.3.1 <i>Fragmentation is the operative secondary pathway in the aggregation of monomeric insulin</i>	227
7.3.2 <i>Glycerol retards the aggregation of insulin and modifies the secondary pathway</i>	230
7.3.3 <i>Seeded aggregation of insulin in the presence of glycerol</i>	233
7.3.4 <i>Analysis of the kinetics of insulin aggregation in the presence and absence of glycerol</i>	236
7.3.5 <i>Imaging of insulin aggregates in presence and absence of glycerol</i>	242

7.3.6 Species formed along the aggregation pathway also seed the aggregation of insulin.....	243
7.3.7 Blocking of aggregation of insulin by glycerol.....	246
7.3.8 Aggregates formed in absence and presence of glycerol show similar seeding capacity.....	248
7.3.9 Monomer-dependent secondary pathway in presence of glycerol can be shifted back to monomer-independent secondary pathway (fragmentation).....	249
7.3.10 A probable mechanism of stabilization of various species in the aggregation pathway of insulin by glycerol.....	250
7.4 Conclusion.....	254
7.5 References.....	256

CHAPTER 8: INVERSE EFFECTS OF ADDITIVES ON THE AGGREGATION AND DISAGGREGATION PATHWAY OF α -SYNUCLEIN

8.1 Introduction.....	263
8.2 Materials and Method.....	265
8.2.1 Materials.....	265
8.2.2 Protein expression and purification.....	266
8.2.3 UV visible spectroscopy.....	266
8.2.4 Aggregation assay.....	267
8.3 Result and discussion.....	267
8.4 Conclusion.....	278
8.5 References.....	280

CHAPTER 9: SUMMARY AND FUTURE PROSPECTS

Summary and future prospects.....285

BIODATA

LIST OF FIGURES

Figure No.	Caption	Page
1.1	Fibrillar aggregates of proteins as observed by AFM (Reference 26) (A), TEM (Reference 27) (B) Fluorescence microscopy (Reference 28) (C) and SEM (Reference 29) (D).	4
1.2	Combined energy landscape for protein folding and aggregation. The troughs denote the numerous conformational states available for a polypeptide chain. The light grey funnel (left) represents the intramolecular folding process while the more rugged dark grey funnel represents the even complex, intermolecular process of protein aggregation. Adapted from Reference 30	5
1.3	Effect of filament fragmentation on actin polymerization in presence of magnesium ions: Dotted lines show the curves that were calculated with the assumption that no fragmentation occurs. Solid lines show the curves that were calculated with the assumption that fragmentation occurs. Adapted from Reference 57	16
1.4	Schematic representation of the various process in the aggregation pathway.	18
1.5	Schematic representation of the various models of aggregation	23
1.6	Free energy profiles for nucleated and downhill polymerization, as a function of the number of monomers	26
1.7	Relative free energy of the aggregates above and below the super critical concentration and the structural and the thermodynamic nuclei in these regions	30
1.8	Transition from an exponential growth in presence of fragmentation to a polynomial growth as the rate of fragmentation decreases. Fragmentation rate decreases towards right in both the figures. The figure in the right shows the expanded portion of the initial times. Curves are obtained from the mathematical exercise of the master equation, Equation 1.11. Reprinted from Reference 46	37
1.9	Hypothetical kinetic curves showing abrupt growth in presence of secondary pathways as compared to primary pathways. Completion of reaction in case	39

	of homogeneous and heterogeneous nucleation is slower compared to fragmentation.	
1.10	Kinetic analysis of aggregation inhibition mechanisms. (A) The binding between the inhibitor, I, and the different species in the system leads to specific changes in the microscopic steps of the aggregation process, such as primary nucleation, elongation, or heterogeneous secondary processes. Redirection of the aggregation pathway into alternative off-pathway oligomers can be considered in this scheme as an effective reduction of the nucleation rates. (B) Model simulations of the macroscopic time evolution of fibril formation show how changes in individual specific microscopic aggregation events affect the observed kinetic macroscopic profile in a characteristic way. Adapted from Reference 113	48
2.1	UV-absorbance spectra of BSA in 10 mM Tris, pH 7.5	72
2.2	(A) Fluorescence spectra of insulin, representing the fluorescence from the tyrosine residues. (B) Fluorescence spectra of BSA representing the fluorescence from the tryptophan residues.	74
2.3	(A) Increase in the tyrosine fluorescence of α -synuclein in the presence of CTAB. (B) Decrease in the tyrosine fluorescence of α -synuclein in the presence of copper sulphate.	74
2.4	(A) Red-shift of the tryptophan fluorescence of BSA in the presence of GdnHCl indicating a less polar environment for tryptophan. (B) Blue shift in the tryptophan fluorescence of BSA in the presence of SDS, indicating a more polar environment for tryptophan.	75
2.5	Change in the ANS fluorescence upon binding to the hydrophobic patches of insulin at pH 7. (B) Change in the DCVJ fluorescence upon binding to the aggregates at different time points during the aggregation of BSA.	75
2.6	CD spectra of BSA and α -synuclein in 20 mM Tris, pH 7.5	77
2.7	Size of the aggregates at two different time points during the aggregation of α -synuclein monitored by dynamic light scattering	78
2.8	Change in the distribution of the monomers and oligomers during the aggregation of BSA monitored by SEC. Higher sized species are eluted at lower volumes. The peak at 13.5 mL is for the monomer.	79

3.1	Comparison of the kinetics of the ThT fluorescence (A) and Rayleigh scattering intensity (B) of 20 μ M BSA at 343 K, pH 7.5, in presence and absence of 0.8 M GdnHCl. Graphs in the inset show the same at short times. For a better comparison of the difference in the extent of aggregation, the figures have been normalized from 1, where 1 corresponds to the lowest intensity.	95
3.2	(A) Dependence of the rate of aggregation of BSA as a function of the protein concentration. (B) hydrodynamic diameter of aggregates during the aggregation of BSA in absence of GdnHCl. (C) hydrodynamic diameter of aggregates during the aggregation of BSA in the presence of GdnHCl.	95
3.3	(A) Graph showing the relatively high increase in Rayleigh scattering, suggesting predominantly amorphous aggregation (B) Intrinsic fluorescence of BSA fibril in pH 7.5, 343 K, without cosolute (black) and the disappearance of the fluorescence in presence of 0.8 M GdnHCl, pH 7.5, 343 K (blue) (C) TEM images of BSA fibrils (D) TEM images of BSA aggregated in presence of 0.8 M GdnHCl.	97
3.4	(A) Concentration dependence of the aggregation of BSA in the presence of GdnHCl. The slope of the line is -1.74. (B) Effect of addition of preformed seeds in the aggregation of BSA at 343 K in 0.8 M GdnHCl.	98
3.5	Aggregation of BSA at short time scales monitored by (A) steady state fluorescence (B) stopped flow fluorescence. (C) Aggregation of BSA in different additives at 343 K.	99
3.6	Kinetics of the conformational changes of BSA at 343 K in the presence of GdnHCl monitored by tryptophan fluorescence, ANS fluorescence and ellipticity.	99
3.7	SEC profile of the aggregation of BSA in the absence and presence of GdnHCl. (A) Change in monomer peak of BSA with increasing time during aggregation at 343 K in buffer alone (B) Change in oligomer peak of BSA with increasing time during aggregation at 343 K in buffer alone. Oligomers are formed from the initial times itself (C) Change in the monomer and oligomer content (peak area) of BSA with time during aggregation at 343 K buffer alone. Monomer loss occurs in sync with oligomer formation. (D) Change in monomer peak of BSA with increasing time during aggregation at 343 K in presence of 0.8 M GdnHCl (E) Change in the monomer peak of BSA with increasing time during aggregation at 343 K in presence of 0.8 M	101

GdnHCl. No oligomers were seen initially. (F) Change in the monomer and oligomer content of BSA with time during aggregation at 343 K in 0.8 M GdnHCl. Monomer loss occurs in sync with oligomer formation.

- 3.8 Existence of secondary pathways during the aggregation of BSA at 343 K in the presence of 0.8 M GdnHCl, as seen from a good fit to the relation $\Delta=A(\cosh Bt - 1)$ 105
- 3.9 Determination of the primary and the secondary nucleus size from the kinetic parameters λ and κ . The slope obtained for the monomer concentration dependence of λ is 1.526 and that of κ is 1.501. 107
- 3.10 (A) Aggregation of BSA in the presence of urea. No lag time could be seen. (B) Thermal denaturation of BSA in the presence of different cosolutes (C) Aggregation of BSA in the presence of 0.8 M NaCl. (D) Aggregation of BSA in the presence of 0.8 M urea and 0.8 M NaCl 109
- 3.11 (A) Aggregation of BSA in the presence of 0.8 M GdnHCl (inset) and CaCl₂ monitored by DCVJ fluorescence. (B) Aggregation of BSA monitored by DCVJ fluorescence in the absence of GdnHCl. 111
- 3.12 Occurrence of lag phase in the aggregation kinetics of BSA in presence of 0.8 M MgCl₂ ((A) and (B)) and 0.8 M CaCl₂ ((C) and (D)). (E) Change in the tryptophan fluorescence and ANS fluorescence during the aggregation in 0.8 M CaCl₂ (F) Change in the tryptophan fluorescence and ANS fluorescence during the aggregation in MgCl₂. 112
- 3.13 Change in the zeta potential (A) and electrophoretic mobility (B) of BSA with increasing concentration of GdnHCl 114
- 3.14 (A) Aggregation of BSA at lower concentrations of GdnHCl. (B) and (C) Aggregation of BSA in various concentrations of CaCl₂ and SDS. (D) Effect of preformed aggregates on the aggregation of BSA in the presence of CaCl₂ 115
- 3.15 Relative change in the amyloid and Rayleigh scattering intensity during the aggregation of BSA at different temperatures. 116
- 3.16 (A) Effect of pH on the aggregation of BSA in presence of Ca²⁺ ions at 343 K. (B) Aggregation of BSA at pH 1.6. (C) Aggregation of BSA at pH 12. 117

	downhill, without any lag phase, whereas the aggregation is nucleated (with a lag phase) when the starting population is (b) (343 K)	
4.1	(A) Aggregation of 40 μ M BSA in different concentrations of urea at 343 K. (B) Rate of aggregation of BSA in different concentrations of urea.	132
4.2	(A) Thermal unfolding of BSA in the presence of different concentrations of urea. (B) Chemical unfolding of BSA in the presence of urea at in 20 mM Tris buffer, pH 7.5	132
4.3	Evolution of the size of aggregates of BSA formed at 343 K in the presence of urea.	133
4.4	(A) Aggregation of BSA in the presence of 3 M urea at different temperatures (B) Rate of aggregation of BSA in the presence of urea at different temperatures.	134
4.5	(A) Thermal denaturation of BSA in the presence of different concentrations of arginine (B) Aggregation of BSA in the presence of different concentration of arginine monitored by DLS. (C) Evolution of the size of aggregates and the rate of aggregation of BSA in the presence of different concentrations of arginine.	135
4.6	(A) Thermal denaturation of BSA in the presence of urea and/or arginine. (B) Variation in the rate and size of aggregates of BSA formed in 1 M urea and different concentrations of arginine.	136
4.7	(A) Kinetics of unfolding in urea in the presence and absence of arginine monitored by ANS fluorescence. (B) Comparison of the rate of aggregation and rate of unfolding in urea in the presence and absence of arginine	137
4.8	(A) Thermal denaturation of BSA in the presence of ethanol (B) Aggregation of BSA at 343 K in the presence of different concentrations of ethanol (C) Change in the rate of aggregation of BSA with increasing concentrations of ethanol.	137
4.9	Native-Gel electrophoresis of the aggregates of BSA formed after 1 hour in the presence of different additives. Lane 1: No additive, time t=0, Lane 2: No additive, Lane 3: 3M urea, Lane 4: 100 mM arginine, Lane 5: 3M urea+100mM arginine, Lane 6: 20% ethanol	138

4.10	Plausible changes in the energy profile in the presence of additives during the aggregation of BSA.	139
4.11	Aggregation prone regions of BSA as analyzed using PASTA and Aggrescan	142
5.1	Aggregation of BSA in the presence of 1.2 mM CTAB, pH 7, at 321 K (A) without stirring (B) with stirring. Red lines show the representative fits to Equation 5.1 (for (A)) and Equation 5.2 (for (B))	153
5.2	Aggregation of the BSA-CTAB system monitored at different wavelengths.	154
5.3	(A) Aggregation of BSA with 1.2 mM CTAB, pH 7, 321 K at different glycerol concentrations under stirred conditions. Red lines show the fits to the kinetic traces. (B)Rate of aggregation in the two phases extracted upon fitting with Equation 5.2.	155
5.4	(A) Aggregation of the supernatant at 321 K obtained from P1 region in the stirred aggregation of BSA in the presence of CTAB. (B) Aggregation of the same solution as in (A) in the presence of aggregates formed in the P1 region. (C) Aggregation (at 321 K) of the supernatant left at the saturation phase of the unstirred aggregation (321 K). (D) Aggregation of the supernatant at 321 K obtained from P2 region in the stirred aggregation of BSA in the presence of CTAB. Red lines in (A), (B) and (D) are the fits to the kinetic traces.	157
5.5	(A) Fluorescence spectra of BSA in the presence of CTAB (B) Fluorescence spectra of the aggregates of BSA dissolved in fresh buffer at 321 K at different time points (C) Native PAGE of the aggregates of BSA dissolved in fresh buffer at 321 K at different time points	159
5.6	(A) BSA in the presence of CTAB was aggregated under unstirred condition and then the solution was stirred using a magnetic bead. Growth could be seen again. (B) BSA in the presence of CTAB was aggregated under unstirred conditions and then agitated with a pipette for some time. A growth phase was observed again.	160
5.7	Size exclusion profiles after stirring a solution of BSA in presence of CTAB which was aggregated at 321 K under unstirred conditions. The trace for '0 mins' refers to the supernatant obtained immediately upon the attainment of saturation. (B) Size exclusion profile of the supernatant of BSA aggregation in the presence of CTAB at 333 K	160

	saturation. (B) Size exclusion profile of the supernatant of BSA aggregation in the presence of CTAB at 333 K	
5.8	(A) Time evolution of the oligomer and monomer content of the stirred aggregation of BSA in presence of CTAB at 321 K	161
5.9	Aggregates viewed under the optical microscope upon staining with Congo red at different time points -(A) 2 minutes (B) 3 minutes (C) 5 minutes (D) 6 minutes (E) 8 minutes (F) 10 minutes	162
5.10	Turbidity profile of the unstirred aggregation of BSA in the presence of CTAB at longer times	162
5.11	(A) Aggregation of the BSA-CTAB system with different concentrations of aggregates added at time $t=0$. (B) Simulated traces of the proposed kinetic scheme showing the effect of addition of different concentrations of aggregates, represented as D. The parameters are used $k_{+1}=7$, $k_{-1}=6$, $k_{+2}=3$, $k_{-2}=0.05$, $k_{+3}=3$, $k_{-3}=0.05$, $k_{+4}=0$, $k_{-4}=0$. k_{+1} , k_{-1} , k_{-2} , k_{-3} , k_{-4} has units of $(\text{time})^{-1}$ while the other rate constants have the unit of $(\text{Concentration})^{-1}(\text{time})^{-1}$	163
5.12	(A) Simulated kinetic traces using the proposed model showing the effect of increasing rate of condensation (k_{+4}) on the aggregation. The parameters used are $k_{+1}=7$, $k_{-1}=6$, $k_{+2}=3$, $k_{-2}=0.05$, $k_{+3}=3$, $k_{-3}=0.05$, $k_{-4}=0$. D refers to the insoluble oligomers of C, as given in the reaction scheme. k_{+1} has units of $(\text{time})^{-1}$ while the other rate constants have the unit of $(\text{concentration})^{-1}(\text{time})^{-1}$ (B) Effect of stirring on the aggregation of the BSA-CTAB system. Arrow points towards increasing stirring speed.	166
5.13	(A) Aggregation of BSA in the presence of 1.2 mM CTAB with different concentrations of BSA (B) Rate of aggregation of the two phases extracted by fitting using Equation 5.2 (C) log-log plot of the half time of the two phases versus the concentration of the protein.	167
5.14	(A) Aggregation of BSA in the presence of 1.2 mM CTAB at different temperatures (B) Rate of aggregation of the two phases extracted by fitting using Equation 5.2 (C) Activation enthalpy and activation entropy of the aggregation extracted using the Eyring Equation.	168
5.15	Absorbance of the residual soluble protein remaining at the end of stirred and unstirred aggregation. Inset shows the absorbance spectra of the soluble protein at 280 nm	169

6.1	(A)Far –UV CD spectra (B) Near UV CD spectra of insulin (15 μ M) in 25mM HCl (pH 1.6) at different temperatures (C) Fraction of helices and strands in insulin (15 μ M) in 25 mM HCl (pH 1.6) at different temperatures	184
6.2	Aggregation kinetics of 15 μ M insulin in presence of various additives at 333 K	185
6.3	(A) Far UV CD spectra of insulin at 298 K in presence of different additives. (B), (C) and (D) Change in the CD spectra of insulin at 333 K in presence of different additives	187
6.4	Percentage loss of helicity (A) and percentage gain in the beta strands (B) at the temperature of aggregation. Percentage change in the secondary structure was calculated using the change in the fraction of secondary structure at 298 K and 333 K, as obtained from the Continll fitting algorithm.	187
6.5	Fluorescence microscopy images of ThT stained aggregates of insulin formed in (A) absence of any additive and in the presence of (B) 0.15 M mannitol (C) 0.15 M sucrose (D) 0.15 M ethylene glycol	191
6.6	Aggregation kinetics of insulin in the presence of different additives. The concentrations of the additive are such that the viscosity of the medium is same.	191
6.7	Arrhenius plots of the lag phase and the growth phase duirng the aggregation of insulin in the presence of different additives.	193
6.8	(A) Fluorescence spectra of ANS in presence of insulin (15 μ M) in 25 mM HCl (pH 1.6), 0.1M NaCl, from 283 K to 363 K. (B) Wavelength maxima of ANS at different temperatures	195
6.9	Change in fluorescence spectra of ANS in presence of insulin (15 μ M) in 25mM HCl (pH 1.6), at 333K in absence of additive (A) and in 0.15 M Mannitol (B) ,0.15 M Sucrose (C) and 0.15 M Ethylene Glycol (D)	196
6.10	Aggregation of insulin (34 μ M) in the presence of different concentration of NaCl in the absence of any additive (A) and in the presence of (B) 0.15 M Mannitol (C) 0.15 M Ethylene Glycol (D) 0.15 M Sucrose	197
6.11	Aggregation of (A)15 μ M insulin at pH 4 and (B) 25 μ M insulin at pH 7 in 0.1 M NaCl in the presence of different additives at 333 K, inset :aggregation of 15 μ M at pH 7 (333 K)	198

6.12	(A) Insulin aggregation as a function of insulin concentration at 333 K in 25mM HCl (pH 1.6) and 0.1M NaCl. (B) Dependence of the apparent rate constant on the concentration of insulin. The red line is the linear fit to the data points. (C) Linear dependence of the scattering at 600 nm to the concentration of protein (D) Plot of the log (lag time) versus log (concentration of insulin) to estimate the size of nucleus.	200
6.13	(A) Reversibility of the unfolding of insulin at 333 K. (B) Ellipticity of insulin at 298 K and 333 K, and the change in the ellipticity of insulin during its aggregation at 333 K in 0.1 M NaCl, pH 1.6. as a function of time.	201
6.14	Check for the reversibility of aggregation. Graph A shows the scattering response of a solution at 333 K which was already aggregated till completion. After the completion of aggregation, the solution was cooled to room temperature first, and then again let to aggregate (B) Aggregation at 333 K was stopped at the growth phase, cooled and then again let to aggregate at 333 K. The graph shows the scattering response (at 333 K) of the cooled solution (C) Aggregation was stopped at the lag phase, cooled and then again let to aggregate.	202
6.15	Modulation of the energy profile in the presence of mannitol	205
6.16	Modulation of the energy profile in the presence of ethylene glycol and sucrose	206
7.1	Presence of secondary pathways in the aggregation of insulin in 20 % acetic acid, pH 2.0 at 323 K. Red line shows the fit to the form $\Delta = A(\cosh Bt - 1)$	228
7.2	(A) Aggregation of insulin in 20% acetic acid, 0.5M NaCl, at 323 K in different insulin concentrations. The continuous lines show the fits to the analytical solutions representing the fragmentation of fibrils. (B) Log-log plot of the half time of aggregation in different concentrations of insulin. The half time of aggregation has been extracted from the parameters obtained from the fits to Equation 7.1	228
7.3	(A) Aggregation of 4 mg/mL insulin in presence of glycerol. Continuous lines represents the fits of the curves to Equation 7.1. (b) Variation of final ThT fluorescence with concentration of glycerol. (C) Percentage of monomer left at the end of aggregation in different concentrations of glycerol. (D)Variation of the lag time and the rate of aggregation in the presence of glycerol as determined from the fit to Equation 7.1	229

7.4	(A) Aggregation of different concentrations of insulin in 20% acetic acid, 0.5M NaCl, at 323 K in 2M glycerol. The continuous lines represents the sigmoidal fits to Equation 1. (B) Log-log plot of the half time of aggregation in presence of 2M glycerol vs the concentration of insulin. The half time has been extracted from the parameters obtained from the fits to Equation 7.1.	232
7.5	(A) Existence of secondary pathways in the aggregation of insulin in 20% acetic acid and 2 M glycerol. (B) The kinetic traces could not be fit (using AmyloFit) to a model that considers only primary pathways.	234
7.6	(A) Aggregation of different concentrations of insulin in 20% acetic acid, 0.5 M NaCl, at 323 K in presence of 1% seeds and 2 M glycerol. Continuous lines represents fits to the curves using “Amylofit” (B) Aggregation of 1 mg/mL insulin in 15 % seeds in 20% acetic acid, 0.5 M NaCl, at 323 K at different concentrations of glycerol	235
7.7	Effect of glycerol on the rate of elongation of the aggregation of insulin in the presence of 15% seeds	236
7.8	(A) Aggregation of 4mg/mL insulin in 20% acetic acid, 0.5M NaCl, at 323 K in varying concentrations of glycerol. The continuous lines represents curves obtained by fitting the data to the analytical solutions for proliferation of aggregates by both fragmentation ($n_c=2$) and monomer-dependent secondary nucleation ($n_c=n_2=2$), using the modified form of κ (κ') which considers both the aforesaid pathways. (B) Plot of the parameters obtained from (A). Left axis represents the rate constants dependent on the primary pathways and right axis represents the rate constant of the monomer-dependent secondary pathways. Figure in the inset shows the variation of rate constants governing the fragmentation (C) Ratio of the parameters representing the secondary pathways and primary pathways. The relative contribution of the secondary pathways increases drastically at higher glycerol concentration. Graph in the inset shows the ratio at lower glycerol concentrations	238
7.9	Arrhenius plots for the lag phase (A) and growth phase (B) in different concentrations of glycerol. (C) Activation energy (D) enthalpy of activation (E) free energy of activation and (F) entropy of activation for the lag phase and the growth phase in different concentrations of glycerol.	241

7.10	TEM images of aggregates formed in (A) absence of glycerol and (B) presence of 2M glycerol. Fluorescence microscopy images of aggregates formed in (C) absence of glycerol (D) and presence of 2M glycerol	243
7.11	Fluorescence microscopy images of species collected at different stages of aggregation –(b) mid-nucleation (c) end-nucleation, (d)-growth phase. These species were separately added to fresh monomeric insulin in absence and presence of glycerol. All of them were capable of seeding the reaction. (a) is ThT alone in 20% acetic acid and 0.5 M NaCl.	244
7.12	Aggregation of 1.5 mg/mL insulin in 20% acetic acid, 0.5 M NaCl, at 323 K presence of species added from various time points of aggregation in absence of glycerol (A) and presence of 2M glycerol (B)	245
7.13	Blocking of aggregation by glycerol: glycerol at a final concentration of 2M was added during the (A) mid lag phase (red dots) and equal volume was added in the control reaction (black squares) (B) end lag phase (red dots) and equal volume was added in the control reaction (black squares) (C) growth phase (red dots) and equal volume was added in the control reaction (black squares) (D) saturation phase (red dots) and equal volume was added in the control reaction (black squares). The black dotted arrows show the time points where glycerol was added.	247
7.14	Aggregation in 0M glycerol (1 and 2) and 2M glycerol (3 and 4) in presence of seeds formed in 0M glycerol (black squares and blue triangle) and in presence of 2M glycerol (red circles and green triangles)	248
7.15	(A) Aggregation of insulin in 20% acetic acid, 0.5 M NaCl, 323 K and 250 rpm in the presence of 2 M glycerol. Continuous lines show fits to Equation 1. (B) Concentration dependence of insulin on the half time of aggregation (C) Fluorescence microscopy images of insulin aggregates in 2 M glycerol formed under agitation at 250 rpm.	249
7.16	Thermal denaturation of insulin in the (A) absence and (B) presence of 0.25M acrylamide and different concentrations of glycerol	251
7.17	ITC profiles of insulin with glycerol at 323 K	251
7.18	Proposed energy profile of the aggregation of insulin in the presence and absence of glycerol	253

8.1	Aggregation of 35 μ M α -synuclein in the presence of different additives: (A) 2 mM Cu(II), (B) 2 M glycerol and (C) 0.1 M GdnHCl.	267
8.2	Spectra of the adduct of α -synuclein with dopamine formed in the presence of different additives	269
8.3	SDS-PAGE of α -synuclein aggregates in the presence of dopamine with or without additives	270
8.4	SDS-PAGE of the α -synuclein aggregates formed in the presence of different concentrations of copper. Lane 1 - 0 mM Copper, Lane 2 - 0.5 mM Copper, Lane 3 - 1 mM Copper, Lane 4 - 3 mM Copper	271
8.5	SDS-PAGE of the aggregation of α -synuclein in the presence of dopamine and different concentrations of glycerol	272
8.6	DLS of the (A) aggregates formed in the presence of dopamine and glycerol and (B) aggregates treated with SDS for 24 hours	273
8.7	UV absorbance spectra of dopamine with increasing time in (A) buffer (20 mM Tris, 0.1 M NaCl, pH 7.5) and (B) Buffer and 35 μ M α -synuclein. Change in the absorbance of dopamine at 453 nm in the (C) presence and (D) absence of 35 μ M α -synuclein.	274
8.8	Absorbance spectra of dopamine in the presence of copper in (A) buffer (B) buffer and 35 μ M α -synuclein. (C) Change in the absorbance at 407 nm with time in the absence and presence of α -synuclein (D) Shift of the wavelength maxima of dopamine in buffer in the absence and presence of copper.	275
8.9	ATR- IR spectra of 6 mM dopamine with increasing time in the absence and presence of copper in the different regions of the IR spectrum. Red and black lines represent the spectra of dopamine in absence of copper at 0 minutes and 7 minutes respectively. Blue and green lines represents the spectra of dopamine in the presence of copper at 0 minutes and 7 minutes respectively.	276
8.10	Change in the absorbance of dopamine in the presence of glycerol in tris buffer, pH 7.5, and 0.1 M NaCl with increasing time	277
8.11	Dopamine- induced disaggregation of the fibrils formed in absence (Lane 1) and presence (Lane 2) of copper	279

LIST OF TABLES

Table No.	Title	Page
1.1	Representation of the terms contained in the Master equation (Equation 1.4)	12
6.1	Density and viscosity of different additives and the kinetic parameters of insulin aggregation (15 μM) in their presence at 333 K in 25mM HCl (pH 1.6) and 0.1M NaCl	185
6.2	Kinetic parameter, (t_{lag} / min) and ($k_{\text{app}}/\text{min}^{-1}$) of the aggregation of insulin (15 μM) in the absence/presence of additives as a function of temperature. The additives were at the following concentrations-0.92 M ethylene glycol, 0.3 M mannitol, 0.15 M sucrose.	194
6.3	Parameters for the formation of a transition state during the catalytic growth of insulin aggregates. The additives were at the following concentration: (1) 0.92M ethylene glycol (2) 0.3M mannitol (3) 0.15M sucrose	194
6.4	Summarization of the effect of the additives on the various stages	209
7.1	Variation of the scaling exponent (γ) of the aggregation of insulin with glycerol concentration	232

LIST OF SCHEMES

Scheme No.	Caption	Page
3.1	Change in the aggregation pathway of BSA from downhill polymerization to nucleated polymerization	121
5.1	Modulation of the aggregation pathway of BSA in the presence of CTAB under stirred conditions	170
6.1	Proposed scheme for the aggregation of insulin at 25 mM HCl, 0.1 M NaCl, pH 1.6	202
7.1	Overall aggregation pathway of monomeric insulin in the presence of glycerol	254

LIST OF ABBREVIATIONS

AFM	Atomic force microscopy
ANS	Anilino-1-naphthalenesulfonic acid
APS	Ammonium persulphate
BSA	Bovine serum albumin
CTAB	Cetyltrimethylammonium bromide
DCM	Dichloromethane
DCVJ	9-(2,2-Dicyanovinyl) julolidine
DLS	Dynamic light scattering
EPR	Electron paramagnetic resonance
FPLC	Fast protein liquid chromatography
GdnHCl	Guanidinium hydrochloride
HSA	Human serum albumin
IAPP	Islet amyloid polypeptide
ITC	Isothermal titration calorimetry
IFN- γ	Interferon gamma
LENP	Lumry Eyring nucleated polymerization
MPL	mass-per-length
PAGE	Polyacrylamide gel electrophoresis
RP-HPLC	Reverse phase high performance liquid chromatography
SDS	Sodium dodecyl sulphate
SEC	Size exclusion chromatography
SEM	Scanning electron microscopy
SOD1	Superoxide dismutase 1
ssNMR	Solid state nuclear magnetic resonance spectroscopy
STEM	Scanning tunneling electron microscope
TEM	Transmission electron microscopy
TEMED	Tetramethylethylenediamine
TFE	Trifluoroethanol
ThT	Thioflavin T
TIRFM	Total internal reflection fluorescence microscopy
TTR	Transthyretin
UV	Ultraviolet